evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

87 questions · 90 findings · 34 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 18 · 20%GRADE not reported 11 · 12.2%Very low 12 · 13.3%Low 20 · 22.2%Moderate 14 · 15.6%High 15 · 16.7%

Intervention not reported

Cancer mortality in trials using vitamin D3 (cholecalciferol) ( · adults

The intervention probably leads to lower cancer mortality in trials using vitamin D3 (cholecalciferol) ( (moderate certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality in trials using vitamin D3 (cholecalciferol) ( · adults

The intervention probably leads to lower all‐cause mortality in trials using vitamin D3 (cholecalciferol) ( (moderate certainty).

1 finding from 1 review

Intervention not reported

Cardiovascular mortality in trials using vitamin D3 (cholecalciferol) ( · adults

The intervention showed no clear difference in cardiovascular mortality in trials using vitamin D3… (low certainty).

1 finding from 1 review

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral nutritional supplements vs multivitamin and mineral supplement

All‐cause mortality · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…

Oral nutritional supplements showed no clear difference in mortality compared with multivitamin and mineral supplement (low certainty).

1 finding from 1 review

Summary of findings table ‐ Prothrombin complex concentrates vs any comparator

Mortality within the longest · patients with vitamin K antagonist‐induced bleeding requiring acute intervention

It is very uncertain whether prothrombin complex concentrate changes overall mortality ‐ longest compared with any comparator (very low certainty).

1 finding from 1 review

Intervention not reported

Mortality · children with measles

The intervention showed no clear difference in mortality (moderate certainty).

1 finding from 1 review

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).

1 finding from 1 review

Aspirin vs vitamin K antagonist (VKA)

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).

1 finding from 1 review